Drug firm Glenmark Pharmaceuticals has achieved positive results in human trials for its new drug molecule Crofelemer, which is aimed at treating diarrhea in adults.Resolution of diarrhea was significantly higher in human subjects, who were given Crofelemer compared to those who were not in a multi-centre trial. Crofelemer will potentially be the first new chemical entity (NCE) to be launched by the organization.
Glenmark will accelerate the development of Crofelemer in the acute indications, including pediatric diarrhea where several million individuals are affected in the geographies that we operate in. Crofelemer is licensed to the company from US-based Napo Pharmaceuticals. In November 2010, Glenmark along with Napo and Salix Pharmaceuticals, had announced the successful completion of phase III trials with Crofelemer for the treatment of diarrhea in patients with HIV in the US.
Glenmark has the exclusive license to develop, commercialise and distribute Crofelemer in 140 emerging countries for indications related to HIV, use in acute diarrhea, including supply to NGOs for delivery within these countries. Glenmark and Salix have also entered into a commercial supply agreement for Crofelemer active pharmaceutical ingredient,crackcrack
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1453.25 |
Dr. Reddys Lab | 5792.95 |
Cipla | 1459.85 |
Zydus Lifesciences | 1032.25 |
Lupin | 1583.95 |
View more.. |